Merus N.V. (Nasdaq: MRUS) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the Biologics License Application (BLA) of zenocutuzumab (Zeno) to February 4, 2025. This extension aims to provide the FDA with adequate time to review recently submitted information related to Chemistry, Manufacturing, and Controls (CMC).
The FDA's decision follows the priority review designation granted to zenocutuzumab for the treatment of patients with NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC) and pancreatic cancer who have received prior therapies. NRG1+ cancers are rare and aggressive tumors driven by fusions involving the NRG1 gene, which dysregulates cell growth and proliferation.
Regulatory Update
The FDA extended the PDUFA goal date to allow sufficient time to review CMC information submitted by Merus. Importantly, the FDA has not requested any additional clinical data, suggesting confidence in the existing clinical trial results supporting the BLA. Merus remains optimistic about the potential approval of zenocutuzumab and its impact on patients with NRG1+ cancers.
Zenocutuzumab: A Biclonics Antibody
Zenocutuzumab is an investigational, full-length bispecific antibody (Biclonics®) designed to bind to both the HER3 receptor and NRG1. By blocking the interaction between NRG1 fusion proteins and HER3, zenocutuzumab aims to inhibit downstream signaling pathways that drive cancer cell growth and survival. This targeted approach offers a potential therapeutic strategy for patients with NRG1+ cancers.
Commercialization Strategy
Merus emphasizes the importance of securing a commercialization partnership agreement to ensure the successful launch and accessibility of zenocutuzumab, if approved. The company believes that a strategic partnership will be vital in bringing this therapy to patients who may benefit from it.
About Merus N.V.
Merus is a clinical-stage oncology company focused on developing innovative, full-length human bispecific and trispecific antibody therapeutics (Multiclonics®). These antibodies are manufactured using industry-standard processes and exhibit characteristics similar to conventional monoclonal antibodies, such as long half-life and low immunogenicity.
